for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Opko Health Inc.

OPK.OQ

Latest Trade

4.13USD

Change

0.18(+4.56%)

Volume

1,183,276

Today's Range

3.96

 - 

4.14

52 Week Range

1.12

 - 

6.47

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.95
Open
3.98
Volume
1,183,276
3M AVG Volume
207.71
Today's High
4.14
Today's Low
3.96
52 Week High
6.47
52 Week Low
1.12
Shares Out (MIL)
670.00
Market Cap (MIL)
2,767.10
Forward P/E
275.33
Dividend (Yield %)
--

Next Event

Q4 2020 OPKO Health Inc Earnings Release

Latest Developments

More

Opko Health Reports 2020 Third Quarter Business Highlights And Financial Results

Pfizer Announces Positive Phase 3 Top-Line Results For Once-Weekly Investigational LongActing Human Growth Hormone To Treat Children With Growth Hormone Deficiency

Opko Health Reports Q2 Earnings Per Share $0.05

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Opko Health Inc.

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Industry

Biotechnology & Drugs

Contact Info

4400 Biscayne Blvd

MIAMI, FL

33137

United States

+1.305.5754181

http://www.opko.com

Executive Leadership

Phillip Frost

Chairman of the Board, Chief Executive Officer

Jane H. Hsiao

Vice Chairman of the Board, Chief Technical Officer

Adam E. Logal

Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer

Jon Roger Cohen

Director, Executive Chairman of BioReference Laboratories

Charles W. Bishop

Chief Executive Officer of OPKO Renal

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.1K

2018

1.0K

2019

0.9K

2020(E)

1.4K
EPS (USD)

2017

-0.490

2018

-0.270

2019

-0.370

2020(E)

0.022
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.38
Price To Book (MRQ)
1.70
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
14.83
LT Debt To Equity (MRQ)
13.90
Return on Investment (TTM)
-5.47
Return on Equity (TTM)
-4.77

Latest News

Latest News

BRIEF-Opko Health's Bioreference Laboratories Reports Results Of Covid-19 Testing For Almost One Quarter

* OPKO HEALTH'S BIOREFERENCE LABORATORIES REPORTS RESULTS OF COVID-19 TESTING FOR ALMOST ONE QUARTER OF A MILLION NURSING HOME AND LIVE-IN FACILITY EMPLOYEES

BRIEF-OPKO Health Reports Positive Results Of Study Of Somatrogon

* OPKO HEALTH ANNOUNCES POSITIVE TOP-LINE RESULTS OF PHASE 3 EFFICACY AND SAFETY STUDY OF SOMATROGON FOR THE TREATMENT OF JAPANESE CHILDREN WITH GROWTH HORMONE DEFICIENCY

CORRECTED-BRIEF-FDA Authorizes OPKO Health Clinical Trial Evaluating Rayaldee In Covid-19 Patients (June 1)

* FDA AUTHORIZES OPKO HEALTH CLINICAL TRIAL EVALUATING RAYALDEE IN COVID-19 PATIENTS

BRIEF-Opko Health Says Entered Amendment To Commercialization License Agreement With Pfizer, Others

* OPKO HEALTH - ON MAY 12, ENTERED AMENDMENT TO COMMERCIALIZATION LICENSE AGREEMENT WITH PFIZER, OTHERS

BRIEF-OPKO Health's Bioreference Laboratories Launches Covid-19 Antibody Screening For New York City Residents

* OPKO HEALTH'S BIOREFERENCE LABORATORIES LAUNCHES COVID-19 ANTIBODY SCREENING FOR NEW YORK CITY RESIDENTS

BRIEF-OPKO Health's Bioreference Labs In Partnership With New York State Initiates Testing For COVID-19 Antibodies

* OPKO HEALTH'S BIOREFERENCE LABORATORIES IN PARTNERSHIP WITH NEW YORK STATE INITIATES TESTING FOR COVID-19 ANTIBODIES

BRIEF-Opko Health's Bioreference Laboratories Partners With Hospitals Nationwide To Provide Prioritized Testing To Inpatients With Suspected Coronavirus Disease 2019 (Covid-19)

* OPKO HEALTH'S BIOREFERENCE LABORATORIES PARTNERS WITH HOSPITALS NATIONWIDE TO PROVIDE PRIORITIZED TESTING TO INPATIENTS WITH SUSPECTED CORONAVIRUS DISEASE 2019 (COVID-19) Source text for Eikon: Further company coverage:

BRIEF-OPKO Health Reports Interim Results For Two Ongoing Rayaldee Studies

* OPKO HEALTH REPORTS INTERIM RESULTS FOR TWO ONGOING RAYALDEE STUDIES

BRIEF-OPKO Health's Bioreference Laboratories And City Of Miami Provide Testing For COVID-19

* OPKO HEALTH'S BIOREFERENCE LABORATORIES AND CITY OF MIAMI PROVIDE TESTING FOR CORONAVIRUS DISEASE 2019 (COVID-19) Source text for Eikon: Further company coverage:

BRIEF-Opko Health's Bioreference Laboratories And City Of Detroit Provide Testing For Coronavirus Disease 2019 (Covid-19)

* OPKO HEALTH'S BIOREFERENCE LABORATORIES AND CITY OF DETROIT PROVIDE TESTING FOR CORONAVIRUS DISEASE 2019 (COVID-19) Source text for Eikon: Further company coverage:

BRIEF-Opko Health's Bioreference Laboratories And State Of New Jersey Provide Testing For Coronavirus Disease 2019 (Covid-19)

* OPKO HEALTH'S BIOREFERENCE LABORATORIES AND STATE OF NEW JERSEY PROVIDE TESTING FOR CORONAVIRUS DISEASE 2019 (COVID-19) Source text for Eikon: Further company coverage:

BRIEF-Opko Health Inc To Collaborate With New York City Health & Hospital Corporation To Provide Coronavirus Disease 2019 Testing

* OPKO HEALTH INC - COLLABORATION WITH NEW YORK CITY HEALTH AND HOSPITAL CORPORATION TO PROVIDE CORONAVIRUS DISEASE 2019 TESTING Source text for Eikon: Further company coverage:

BRIEF-Opko Health Says Bioreference Labs Now Accepting Specimens For Testing Of COVID-19

* OPKO HEALTH - BIOREFERENCE LABORATORIES NOW ACCEPTING SPECIMENS FOR TESTING OF CORONAVIRUS DISEASE 2019

BRIEF-Opko Health's Bioreference Laboratories To Introduce Coronavirus Disease (Covid-19) Test

* OPKO HEALTH'S BIOREFERENCE LABORATORIES TO INTRODUCE CORONAVIRUS DISEASE (COVID-19) TEST

BRIEF-Opko Health Reports Fourth-Quarter Results

* OPKO HEALTH REPORTS 2019 FOURTH QUARTER BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS

Opko Health says over 400,000 customers likely affected by data breach

Opko Health Inc said on Thursday it was notified by its former billing collections vendor about unauthorized access to information on about 422,600 customers, making it the third healthcare company to be affected by the incident.

UPDATE 1-IFR Americas ECM Pipeline

PRICED Invesco Mortgage Capital (US, mortgage REIT) – $220m Block. 14m shares (100% prim) at $15.73 versus $15.73 fixed-price marketing and $16.30 last sale. MS, CITI, CS. Marcus Corporation (US, movie theaters) – $60.4m Block. 1.5m shares (100% sec) at $40.25 versus $40.25...

BRIEF-Opko Plans To Address Draft Local Coverage Determination Published By Novitas Solutions For 4Kscore Test

* OPKO PLANS TO ADDRESS DRAFT LOCAL COVERAGE DETERMINATION PUBLISHED BY NOVITAS SOLUTIONS FOR 4KSCORE TEST Source text for Eikon: Further company coverage:

BRIEF-Opko Health Reports Q1 Loss Per Share Of $0.08

* Q1 REVENUE $254.9 MILLION VERSUS I/B/E/S VIEW $236.9 MILLION

BRIEF-OPKO Health Inc Says Intends To Remain On Tel Aviv Stock Exchange

* OPKO HEALTH INC - INTENDS TO REMAIN ON TEL AVIV STOCK EXCHANGE AND WITHDRAW ITS REQUEST TO VOLUNTARILY DELIST ITS COMMON STOCK FROM TASE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up